Siwa Therapeutics
SIWA Therapeutics is a privately held preclinical stage biotechnology company that has a monoclonal antibody that targets and destroys senescent cells. Our current therapeutic focus is on certain rare and fast track diseases, including cancer metastasis and muscle wasting diseases, such as muscular dystrophy. Beyond these indications, senescent cells are causally implicated in a wide variety of diseases including: neurodegenerative diseases; autoimmune conditions, and infectious diseases. SIWA is currently optimizing its lead antibody, SIWA 318, and in parallel, seeking partnerships to advance SIWA 318 and other related technologies to broaden and accelerate its development pipeline.
7-day free trial · no credit card
Verified contacts
5
available on Kipplo
LinkedIn employees
10
1 to 10 range
Open roles
—
no listings
Distinct roles
5
indexed titles
Tech stack
0
tools in use
Monthly traffic
—
organic / mo
Sign up free to see all 5 verified contacts at Siwa Therapeutics
Free for 7 days · 50 credits · no card · only pay for verified records.
Decision-makers and verified team members
5 contacts with verified email or phone · masked until revealed.
- JP
John Peters
Chairman · General Business & Management
EmailPhone - LG
Lewis Gruber
CEO & Chief Scientific Officer · Other
EmailPhone - MG
Misty Gruber
Chief Administrative Officer · General Business & Management
EmailPhone
Showing 3 of 5 verified contacts
Top roles at Siwa Therapeutics
5 distinct titles indexed · top 5 shown.
- 1ceo & chief scientific officer
- 1chairman
- 1chief administrative officer
- 1electrical engineer
- 1guard
Sign up to unlock all 5 contacts at Siwa Therapeutics
Free for 7 days · 50 credits · no card · only pay for verified records.
Sign up to reveal 5 verified contacts at Siwa Therapeutics
7-day trial · no credit card · cancel anytime · only pay for verified records.
Trusted by sales, marketing, and GTM engineering teams.